Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-24T01:09:33.944Z Has data issue: false hasContentIssue false

Repeated treatment with nitric oxide synthase inhibitor attenuates learned helplessness development in rats and increases hippocampal BDNF expression

Published online by Cambridge University Press:  20 November 2017

Laura Alves Stanquini
Affiliation:
Laboratory of Pharmacology, Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), University of São Paulo, Ribeirão Preto, SP, Brazil Department of Pharmacology, School of Medicine of Ribeirão Preto (FMRP), University of São Paulo, Ribeirão Preto, SP, Brazil
Caroline Biojone
Affiliation:
Laboratory of Pharmacology, Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), University of São Paulo, Ribeirão Preto, SP, Brazil Department of Pharmacology, School of Medicine of Ribeirão Preto (FMRP), University of São Paulo, Ribeirão Preto, SP, Brazil
Francisco Silveira Guimarães
Affiliation:
Department of Pharmacology, School of Medicine of Ribeirão Preto (FMRP), University of São Paulo, Ribeirão Preto, SP, Brazil Center for Interdisciplinary Research on Applied Neurosciences (NAPNA) from University of São Paulo, SP, Brazil
Sâmia Regiane Joca*
Affiliation:
Laboratory of Pharmacology, Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), University of São Paulo, Ribeirão Preto, SP, Brazil Center for Interdisciplinary Research on Applied Neurosciences (NAPNA) from University of São Paulo, SP, Brazil
*
Dr. Sâmia R. L. Joca, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), University of São Paulo, Avenida do café s/n, 14040-903, Ribeirão Preto, SP, Brazil. Tel: +55 16 36024705; Fax: +55 16 36024880; E-mail: samia@usp.br

Abstract

Background

Nitric oxide synthase (NOS) inhibitors induce antidepressant-like effects in animal models sensitive to acute drug treatment such as the forced swimming test. However, it is not yet clear if repeated treatment with these drugs is required to induce antidepressant-like effects in preclinical models.

Objective

The aim of this study was to test the effect induced by acute or repeated (7 days) treatment with 7-nitroindazole (7-NI), a preferential inhibitor of neuronal NOS, in rats submitted to the learned helplessness (LH) model. In addition, we aimed at investigating if 7-NI treatment would increase brain-derived neurotrophic factor (BDNF) protein levels in the hippocampus, similarly to the effect of prototype antidepressants.

Methods

Animals were submitted to a pre-test (PT) session with inescapable footshocks or habituation (no shocks) to the experimental shuttle box. Six days later they were exposed to a test with escapable footshocks. Independent groups received acute (a single injection after PT or before test) or repeated (once a day for 7 days) treatment with vehicle or 7-NI (30 mg/kg).

Results

Repeated, but not acute, treatment with 7-NI attenuated LH development. The effect was similar to repeated imipramine treatment. Moreover, in an independent experimental group, only repeated treatment with 7-NI and imipramine increased BDNF protein levels in the hippocampus.

Conclusion

The results suggest the nitrergic system could be a target for the treatment of depressive-like conditions. They also indicate that, similar to the positive control imipramine, the antidepressant-like effects of NOS inhibition could involve an increase in hippocampal BDNF levels.

Type
Original Article
Copyright
© Scandinavian College of Neuropsychopharmacology 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Schildkraut, JJ, Kety, SS. Biogenic amines and emotion. Science. 1967;156:2137.Google Scholar
2. Heninger, GR, Delgado, PL, Charney, DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:211.Google Scholar
3. Castren, E. Is mood chemistry? Nat Rev Neurosci 2005;6:241246.Google Scholar
4. Blier, P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol. 2003;13:5766.Google Scholar
5. Kiss, JP. Theory of active antidepressants: a nonsynaptic approach to the treatment of depression. Neurochem Int. 2008;52:3439.Google Scholar
6. Kiss, JP. Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull 2000;52:459466.Google Scholar
7. Guix, FX, Uribesalgo, I, Coma, M, Munoz, FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol. 2005;76:126152.Google Scholar
8. Moncada, S, Bolanos, JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006;97:16761689.Google Scholar
9. Joca, SR, Guimaraes, FS, Del-Bel, E. Inhibition of nitric oxide synthase increases synaptophysin mRNA expression in the hippocampal formation of rats. Neurosci Lett. 2007;421:7276.Google Scholar
10. Garthwaite, J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008;27:27832802.Google Scholar
11. Paakkari, I, Lindsberg, P. Nitric oxide in the central nervous system. Ann Med. 1995;27:369377.Google Scholar
12. Moreno-Lopez, B, Noval, JA, Gonzalez-Bonet, LG, Estrada, C. Morphological bases for a role of nitric oxide in adult neurogenesis. Brain Res. 2000;869:244250.Google Scholar
13. Garthwaite, J, Charles, SL, Chess-Williams, R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 1988;336:385388.Google Scholar
14. Prast, H, Philippu, A. Nitric oxide as modulator of neuronal function. Prog Neurobiol. 2001;64:5168.Google Scholar
15. Brenman, JE, Bredt, DS. Synaptic signaling by nitric oxide. Curr Opin Neurobiol 1997;7:374378.Google Scholar
16. Trullas, R, Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:110.Google Scholar
17. Petrie, RX, Reid, IC, Stewart, CA. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol Ther. 2000;87:1125.Google Scholar
18. Jefferys, D, Funder, J. Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur J Pharmacol 1996;295:131135.Google Scholar
19. Joca, SR, Moreira, FA, Wegener, G. Atypical Neurotransmitters and the neurobiology of depression. CNS Neurol Disord Drug Targets 2015;14:10011011.Google Scholar
20. Ulak, G, Mutlu, O, Tanyeri, P, Komsuoglu, FI, Akar, FY, Erden, BF. Involvement of serotonin receptor subtypes in the antidepressant-like effect of TRIM in the rat forced swimming test. Pharmacol Biochem Behav 2010;95:308314.Google Scholar
21. Yildiz, F, Erden, BF, Ulak, G, Utkan, T, Gacar, N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 2000;149:4144.Google Scholar
22. Joca, SR, Guimaraes, FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006;185:298305.Google Scholar
23. Montezuma, K, Biojone, C, Lisboa, SF, Cunha, FQ, Guimaraes, FS, Joca, SR. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology. 2012;62:485491.Google Scholar
24. Wegener, G, Harvey, BH, Bonefeld, B et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J Neuropsychopharmacol 2010;13:461473.Google Scholar
25. Wegener, G, Volke, V, Harvey, BH, Rosenberg, R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 2003;959:128134.Google Scholar
26. Harvey, BH, Retief, R, Korff, A, Wegener, G. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. Metab Brain Dis 2006;21:211220.Google Scholar
27. Suzuki, E, Yagi, G, Nakaki, T, Kanba, S, Asai, M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001;63:221224.Google Scholar
28. Oliveira, RM, Guimaraes, FS, Deakin, JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41:333341.Google Scholar
29. Naylor, GJ, Smith, AH, Connelly, P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry. 1987;22:657659.Google Scholar
30. Wegener, G, Volke, V. Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals (Basel) 2010;3:273299.Google Scholar
31. Berman, RM, Cappiello, A, Anand, A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351354.Google Scholar
32. Duman, RS, Li, N, Liu, RJ, Duric, V, Aghajanian, G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012;62:3541.Google Scholar
33. Abdallah, CG, Sanacora, G, Duman, RS, Krystal, JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 2015;66:509523.Google Scholar
34. Maier, SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:435446.Google Scholar
35. Sherman, AD, Sacquitne, JL, Petty, F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982;16:449454.Google Scholar
36. Willner, P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:677690.Google Scholar
37 Willner, P. Animal models of depression: an overview. Pharmacol Ther 1990;45:425455.Google Scholar
38. Castren, E, Rantamaki, T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 2010;70:289297.Google Scholar
39. Bjorkholm, C, Monteggia, LM. BDNF – a key transducer of antidepressant effects. Neuropharmacology. 2016;102:7279.Google Scholar
40. Duman, RS, Heninger, GR, Nestler, EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597606.Google Scholar
41. Duman, RS, Monteggia, LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:11161127.Google Scholar
42. Canossa, M, Giordano, E, Cappello, S, Guarnieri, C, Ferri, S. Nitric oxide down-regulates brain-derived neurotrophic factor secretion in cultured hippocampal neurons. Proc Natl Acad Sci USA 2002;99:32823287.Google Scholar
43. Yazir, Y, Utkan, T, Aricioglu, F. Inhibition of neuronal nitric oxide synthase and soluble guanylate cyclase prevents depression-like behaviour in rats exposed to chronic unpredictable mild stress. Basic Clin Pharmacol Toxicol 2012;111:154160.Google Scholar
44. Joca, SR, Padovan, CM, Guimaraes, FS. Activation of post-synaptic 5-HT(1A) receptors in the dorsal hippocampus prevents learned helplessness development. Brain Res. 2003;978:177184.Google Scholar
45. Bush, MA, Pollack, GM. Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus. Pharm Res 2001;18:16071612.Google Scholar
46. Zhou, QG, Hu, Y, Hua, Y et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem. 2007;103:18431854.Google Scholar
47. Joca, SR, Zanelati, T, Guimaraes, FS. Post-stress facilitation of serotonergic, but not noradrenergic, neurotransmission in the dorsal hippocampus prevents learned helplessness development in rats. Brain Res. 2006;1087:6774.Google Scholar
48. Geoffroy, M. Psychomotor stimulants versus antidepressants in the learned helplessness model of depression. Drug Development Research 1993;29:4855.Google Scholar
49. Ghasemi, M, Sadeghipour, H, Mosleh, A, Sadeghipour, HR, Mani, AR, Dehpour, AR. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol. 2008;18:323332.Google Scholar
50. Harkin, AJ, Bruce, KH, Craft, B, Paul, IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999;372:207213.Google Scholar
51. Mutlu, O, Ulak, G, Laugeray, A, Belzung, C. Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol Biochem Behav 2009;92:8287.Google Scholar
52. Willner, P, Mitchell, PJ. The validity of animal models of predisposition to depression. Behav Pharmacol. 2002;13:169188.Google Scholar
53. Porsolt, RD, Le Pichon, M, Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730732.Google Scholar
54. Cryan, JF, Markou, A, Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238245.Google Scholar
55. Saarelainen, T, Hendolin, P, Lucas, G et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 2003;23:349357.Google Scholar
56. Rantamaki, T, Hendolin, P, Kankaanpaa, A et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-C gamma signaling pathways in mouse brain. Neuropsychopharmacology. 2007;32:21522162.Google Scholar
57. Martin, P, Puech, AJ. Antagonism by benzodiazepines of the effects of serotonin-, but not norepinephrine-, uptake blockers in the learned helplessness paradigm in rats. Biol Psychiatry. 1996;39:882890.Google Scholar
58. Pryce, CR, Azzinnari, D, Spinelli, S, Seifritz, E, Tegethoff, M, Meinlschmidt, G. Helplessness: a systematic translational review of theory and evidence for its relevance to understanding and treating depression. Pharmacol Ther. 2011;132:242267.Google Scholar
59 Seligman, MEP. Helplessness: on depression, development, and death. San Francisco: WH Freeman and Company, 1975.Google Scholar
60. de Oliveira, RM, Aparecida Del Bel, E, Mamede-Rosa, ML, Padovan, CM, Deakin, JF, Guimaraes, FS. Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. Neurosci Lett. 2000;289:123126.Google Scholar
61. Maier, SF, Jackson, RL. Learned helplessness: all of us were right (and wrong): inescapable shock has multiple effects. In: Bower B, editor. Advances in Learning and Motivation. New York: Academic Press, 1979; p. 155215.Google Scholar
62. Jackson, RL, Alexander, JH, Maier, SF. Learned helplessness, inactivity, and associative deficits: effects of inescapable shock on response choice escape learning. J Exp Psychol Anim Behav Process 1980;6:120.Google Scholar
63. Minor, TR, Jackson, RL, Maier, SF. Effects of task-irrelevant cues and reinforcement delay on choice-escape learning following inescapable shock: evidence for a deficit in selective attention. J Exp Psychol Anim Behav Process 1984;10:543556.Google Scholar
64. Richter, SH, Zeuch, B, Lankisch, K, Gass, P, Durstewitz, D, Vollmayr, B. Where have I been? Where should I go? Spatial working memory on a radial arm maze in a rat model of depression. PLoS One. 2013;8:e62458.Google Scholar
65. Song, L, Che, W, Min-Wei, W, Murakami, Y, Matsumoto, K. Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 2006;83:186193.Google Scholar
66. Yang, Y, Wang, ZH, Jin, S et al. Opposite monosynaptic scaling of BLP-vCA1 inputs governs hopefulness- and helplessness-modulated spatial learning and memory. Nat Commun. 2016;7:11935.Google Scholar
67. Clark, L, Chamberlain, SR, Sahakian, BJ. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 2009;32:5774.Google Scholar
68. Hammar, A, Ardal, G. Cognitive functioning in major depression--a summary. Front Hum Neurosci 2009;3:26.Google Scholar
69. Marazziti, D, Consoli, G, Picchetti, M, Carlini, M, Faravelli, L. Cognitive impairment in major depression. Eur J Pharmacol 2010;626:8386.Google Scholar
70. Schulz, D, Mirrione, MM, Henn, FA. Cognitive aspects of congenital learned helplessness and its reversal by the monoamine oxidase (MAO)-B inhibitor deprenyl. Neurobiol Learn Mem 2010;93:291301.Google Scholar
71. Bohme, GA, Bon, C, Stutzmann, JM, Doble, A, Blanchard, JC. Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol 1991;199:379381.Google Scholar
72. Schuman, EM, Madison, DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. 1991;254:15031506.Google Scholar
73. Mizutani, A, Saito, H, Abe, K. Involvement of nitric oxide in long-term potentiation in the dentate gyrus in vivo. Brain Res. 1993;605:309311.Google Scholar
74. Chen, W, Yan, M, Wang, Y, Wang, X, Yuan, J, Li, M. Effects of 7-nitroindazole, a selective neural nitric oxide synthase inhibitor, on context-shock associative learning in a two-process contextual fear conditioning paradigm. Neurobiol Learn Mem 2016;134(Pt B):287293.Google Scholar
75. Maier, SF, Grahn, RE, Kalman, BA, Sutton, LC, Wiertelak, EP, Watkins, LR. The role of the amygdala and dorsal raphe nucleus in mediating the behavioral consequences of inescapable shock. Behav Neurosci. 1993;107:377388.Google Scholar
76. Guimaraes, FS, de Aguiar, JC, Del Bel, EA, Ballejo, G. Anxiolytic effect of nitric oxide synthase inhibitors microinjected into the dorsal central grey. Neuroreport. 1994;5:19291932.Google Scholar
77. Spolidorio, PC, Echeverry, MB, Iyomasa, M, Guimaraes, FS, Del Bel, EA. Anxiolytic effects induced by inhibition of the nitric oxide-cGMP pathway in the rat dorsal hippocampus. Psychopharmacology (Berl) 2007;195:183192.Google Scholar
78. Grahn, RE, Watkins, LR, Maier, SF. Impaired escape performance and enhanced conditioned fear in rats following exposure to an uncontrollable stressor are mediated by glutamate and nitric oxide in the dorsal raphe nucleus. Behav Brain Res 2000;112:3341.Google Scholar
79. Lanfumey, L, Mongeau, R, Cohen-Salmon, C, Hamon, M. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev 2008;32:11741184.Google Scholar
80. Castren, E, Voikar, V, Rantamaki, T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007;7:1821.Google Scholar
81. Lucassen, PJ, Meerlo, P, Naylor, AS et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol. 2010;20:117.Google Scholar
82. McEwen, BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism. 2005;54(Suppl. 1):2023.Google Scholar
83. Malberg, JE, Eisch, AJ, Nestler, EJ, Duman, RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:91049110.Google Scholar
84. Nibuya, M, Morinobu, S, Duman, RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:75397547.Google Scholar
85. Santarelli, L, Saxe, M, Gross, C et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805809.Google Scholar
86. Malberg, JE, Duman, RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28:15621571.Google Scholar
87. Moreno-Lopez, B, Romero-Grimaldi, C, Noval, JA, Murillo-Carretero, M, Matarredona, ER, Estrada, C. Nitric oxide is a physiological inhibitor of neurogenesis in the adult mouse subventricular zone and olfactory bulb. J Neurosci. 2004;24:8595.Google Scholar
88. Packer, MA, Stasiv, Y, Benraiss, A et al. Nitric oxide negatively regulates mammalian adult neurogenesis. Proc Natl Acad Sci USA 2003;100:95669571.Google Scholar
89. Biojone, C, Casarotto, PC, Joca, SR, Castren, E. Interplay between nitric oxide and brain-derived neurotrophic factor in neuronal plasticity. CNS Neurol Disord Drug Targets 2015;14:979987.Google Scholar
90. Pinnock, SB, Herbert, J. Brain-derived neurotropic factor and neurogenesis in the adult rat dentate gyrus: interactions with corticosterone. Eur J Neurosci 2008;27:24932500.Google Scholar
91. Wegener, G, Volke, V, Rosenberg, R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 2000;130:575580.Google Scholar
92. Harkin, A, Connor, TJ, Walsh, M, St John, N, Kelly, JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology. 2003;44:616623.Google Scholar
Supplementary material: File

Stanquini et al supplementary material

Stanquini et al supplementary material 1

Download Stanquini et al supplementary material(File)
File 291.3 KB